High temperature hyperthermia treatment for canines exhibiting superficial tumors: A report of three cases

HIDEFUMI TAKAGI1,2*, KAZUO AZUMA3*, TOMOHIRO OSAKI3, NORIHIKO ITOH3, SHINICHI NAKAZUMI4, YASUHO TAURA1 and YOSHIHARU OKAMOTO3

1Department of Clinical Veterinary Science, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi 753-8515; 2Takagi Animal Clinic, Saijo, Ehime 793-0035; 3Department of Veterinary Clinical Science, School of Veterinary Medicine, Faculty of Agriculture, Tottori University, Tottori 680-8533; 4AdMeTech Co., Ltd, Matsuyama 790-0054, Japan

Received January 27, 2014; Accepted June 19, 2014

DOI: 10.3892/ol.2014.2496

Abstract. High temperature hyperthermia (HTH) treatment has previously been demonstrated to suppress tumor growth in a tumor-bearing rat model. In the present study, the effects of HTH therapy for the treatment of spontaneous tumors in canines was evaluated. In case 1, an 18-year-old female Papillon presented with a right forelimb rhabdomyosarcoma. Case 2 was a 13-year-old male English Cocker Spaniel with a right external auditory canal ceruminous adenocarcinoma and case 3 was a 14-year-old male Golden Retriever that exhibited a perianal gland adenocarcinoma, which surrounded the anus. HTH treatment was performed in all three cases for 10 min at 45-65˚C with or without the inhalation of isoflurane. In case 1, the tumor disappeared four weeks following HTH treatment. In case 2, the tumor volume had decreased by day 21, and in case 3, HTH was performed three times and the tumor disappeared following the third procedure. HTH is considered to be a simple procedure with no severe side effects. Consequently, this treatment modality is hypothesized to become a useful alternative therapy for superficial tumors in companion animals.

Introduction

The life span of companion animals has been prolonged by the advent of routine vaccinations, improved nutrition and living environments, and advances in veterinary medicine. As a result, the incidence of aging-associated illnesses has increased in the companion animal population. Specifically, cancer is considered to be a significant issue. As in human medicine, there are three major modalities for cancer treatment within veterinary medicine; surgery, chemotherapy and radiation therapy. However, it is difficult to treat all of the affected animals with these types of therapy due to the cost and the limited number of facilities available. Therefore, the development of novel treatment strategies is required.

Conventional hyperthermia has long been established as a treatment for cancer, particularly for superficially located tumors (1). Conventional hyperthermia is performed alone or as an adjunct to radio- or chemotherapy (2-5) and has previously been adopted to treat spontaneous tumors in veterinary medicine (6-9). Various studies have focused on two common strategies; conventional hyperthermia at mild temperatures (range, 42-45˚C) (1,10,11) and ablation therapy at high temperatures (>70˚C) (12). Our previous study demonstrated that high temperature hyperthermia (HTH) treatment ranging between 60 and 70˚C suppressed glioma tumor growth and induced necrosis and apoptosis in a rat model (13). In the present study, the efficacy of HTH therapy in the treatment of spontaneous tumors in canines is evaluated.

Case report

Case 1. An 18-year-old female Papillon (weight, 3.2 kg) was referred to the Yamaguchi University Veterinary Teaching Hospital (Yamaguchi, Japan) in April, 2010 for evaluation of a right forelimb tumor (Fig. 1A). Surgical excision of the tumor had been performed twice previously, however, the tumor had recurred. Histological analysis revealed that the tumor was a rhabdomyosarcoma. On initial examination, the caudal right forelimb was covered by the tumor and the animal was incapacitated in the affected limb. The risk of recurrence and the treatment options were explained to the owners, which included surgery, radiation therapy and chemotherapy. Complete surgical excision was considered to be too complex, as the tumor border was unclear. HTH experimental therapy was recommended and the animal was enrolled in the clinical trial, with the owners’ written informed consent. A tissue ablation device for veterinary medicine (AMTC 200; AdMeTech Co., Ltd., Ehime,
HTH therapy was performed with no anesthesia or sedation. Three needles of the device were inserted into the tumor tissue at 6-mm intervals and the HTH therapy was performed for 10 min at 65˚C. On day 21, the tumor volume had decreased compared with the volume that was observed on day 0, and the subject had regained improved function of the limb (Fig. 1B). Following four weeks of HTH therapy, the tumor disappeared.

Japan) was used to administer the HTH treatment. On day 0, HTH therapy was performed with no anesthesia or sedation. Three needles of the device were inserted into the tumor tissue at 6-mm intervals and the HTH therapy was performed for 10 min at 65˚C. On day 21, the tumor volume had decreased from that which was observed on day 0, and the subject had regained improved function of the limb (Fig. 1B). Following four weeks of HTH therapy, the tumor disappeared.
Case 2. A 14-year-old male Golden Retriever (weight, 32.7 kg) was referred to the Takagi Animal Clinic (Saijo, Japan) in February, 2011 for the evaluation of a tumor surrounding the anus (Fig. 2A). Biopsy and histopathological analysis identified the tumor as a perianal gland adenocarcinoma. The risk of recurrence and the treatment options were described to the owners, which included surgery, radiation therapy and chemotherapy. Complete surgical excision was considered to be too difficult, as the tumor border was unclear. HTH experimental therapy was recommended and the animal was enrolled in the clinical trial, with the owners' written informed consent. On day 0, HTH therapy was performed under general anesthesia, which was administered by inhalation of isoflurane. Five needles of the device were inserted into the tumor at 1-cm intervals, and HTH was performed for 10 min at 65˚C (Fig. 2B) and repeated one additional time. On day 21, the tumor volume had decreased from that which was observed on day 0 (Fig. 2C). HTH therapy was repeated using the same protocol, however, the dog succumbed one week later due to old age.

Case 3. A 13-year-old male English Cocker Spaniel (weight, 12.3 kg) was referred to the Takagi Animal Clinic in February, 2011 for the evaluation of a tumor in the right external auditory canal (Fig. 3A). A right total ear canal ablation was performed and subsequent histopathological analysis revealed a ceruminous adenocarcinoma. Two months after the intervention, the tumor recurred at the surgical site. The risk of recurrence and the treatment options were explained to the owner, which included surgery, radiation therapy and chemotherapy. Specifically, surgery presented the risks of vestibular disorders and facial paralysis. HTH experimental therapy was recommended and the animal was enrolled in a clinical trial, with the owner's written informed consent. On day 0, HTH therapy was performed under general anesthesia, which was maintained using inhaled isoflurane. Five needles of the device were inserted into the tumor and HTH therapy was performed for 10 min at 65˚C (Fig. 3B). On day 22, the tumor volume had decreased from that which was observed on day 0. On day 28, the HTH therapy was repeated using the same protocol. On day 78, the tumor volume had decreased further and a third HTH procedure was performed. On day 133, the tumor had disappeared and did not recur.

Discussion

To the best of our knowledge, the beneficial effects of HTH therapy for the treatment of superficial tumors have not yet been reported in veterinary medicine. The HTH protocol used in the current study was simple to conduct and was only performed on spontaneous tumors that had presented in canines. In the three cases presented, the tumor volumes decreased following HTH therapy; furthermore, no severe side effects were observed in any of the cases.

In recent years, various innovative and minimally invasive cancer therapies have been developed as alternatives to surgery. Ablation, which uses high temperatures, radio waves or microwaves, is considered to be a potent alternative therapeutic strategy (14).

High temperatures (>46˚C) directly damage cells, resulting in severe protein denaturation and DNA damage (15,16), which induces irreversible changes that ultimately result in cell death. Tumor cells express specific tumor-associated antigens and in high temperature conditions (>46˚C), the tumor cells swell and...
break into fragments, which releases antigens; this large antigen load generates antitumor immunity. The high temperatures also lead to severe protein denaturation that appears to destroy the immunogenicity of tumor cells (17-21). When thermal ablation temperatures (>70°C) are achieved, there is a high risk of shock syndrome that is induced by the sudden and large production of necrotic tumor material (22). Therefore, the case for ablation therapy in medicine is limited. Ablation therapy is commonly performed on tumors measuring ≤3 cm in diameter (23). In the present cases, tumor sizes were >3 cm in diameter, although this was not measured precisely. In our previous study, it was reported that HTH therapy administered at temperatures between 50 and 70°C induces necrosis and apoptosis in a rat glioma model (13). However, HTH therapy at 50°C did not exert adequate suppressive effects when compared with treatment at 60 and 70°C. The present results coincide with our previous data. The optimal therapeutic protocol, including the effective temperature, time and frequency must be established in order to extend the application of HTH therapy for routine use in veterinary oncology.

In conclusion, HTH treatment is a simple therapeutic option with no severe side effects and is expected to become a useful alternative therapy for superficial tumors in companion animals.

References

1. Soares PI, Ferreira IM, Igreja RA, Novo CM and Borges JP: Application of hyperthermia for cancer treatment: recent patents review. Recent Pat Anticancer Drug Discov 7: 64-73, 2012.
2. Wust P, Hildebrandt B, Sreenivasa G, et al: Hyperthermia in combined treatment of cancer. Lancet Oncol 3: 487-497, 2002.
3. Falk MH and Issels RD: Hyperthermia in oncology. Int J Hyperthermia 17: 1-18, 2001.
4. Ross MI: Current status of hyperthermic limb perfusion for in-transit melanoma. Int J Hyperthermia 24: 205-217, 2008.
5. Pennacchioli E, Fiore M and Gronchi A: Hyperthermia as an adjunctive treatment for soft-tissue sarcoma. Expert Rev Anticancer Ther 9: 199-210, 2009.
6. Brewer WG Jr and Turrel JM: Radiotherapy and hyperthermia in the treatment of fibrosarcomas in the dog. J Am Vet Med Assoc 181: 146-150, 1982.
7. Page RL and Thrall DE: Clinical indications and applications of radiotherapy and hyperthermia in veterinary oncology. Vet Clin North Am Small Anim Pract 20: 1075-1092, 1990.
8. Gillette EL: Hyperthermia effects in animals with spontaneous tumors. Natl Cancer Inst Monogr 61: 361-364, 1982.
9. Grier RL, Brewer WG Jr and Theilen GH: Hyperthermic treatment of superficial tumors in cats and dogs. J Am Vet Med Assoc 177: 227-233, 1980.
10. Stojkovic R and Radacic M: Cell killing of melanoma B16 in vivo by hyperthermia and cytotoxins. Int J Hyperthermia 18: 62-71, 2002.
11. Ito A, Fujisaka M, Yoshida T, et al: 4-S-Cysteaminylandphenol-loaded magnetite cationic liposomes for combination therapy of hyperthermia with chemotherapy against malignant melanoma. Cancer Sci 98: 424-430, 2007.
12. Haen SP, Pereira PL, Salih HR, Rammensee HG and Gouttefangeas C: More than just tumor destruction: immunomodulation by thermal ablation of cancer. Clin Dev Immunol 2011: 160250, 2011.
13. Takagi H, Azuma K, Tsuka T, Imagawa T, Osaki T and Okamoto Y: Anti-tumor effects of high-temperature hyperthermia on a glioma rat model. Oncof Lett 7: 1007-1010, 2014.
14. Baisi A, De Simone M, Raveglia F and Cioffi U: Thermal ablation in the treatment of lung cancer: present and future. Eur J Cardiothorac Surg 43: 683-686, 2013.
15. Diederich CF: Thermal ablation and high-temperature thermal therapy: overview of technology and clinical implementation. Int J Hyperthermia 21: 745-753, 2005.
16. Roti Roti JL: Cellular responses to hyperthermia (40-46 degrees C): cell killing and molecular events. Int J Hyperthermia 24: 3-15, 2008.
17. den Brok MH, Sutmuller RP, van der Voort R, Bennink EJ, Figdor CG, Ruers TJ and Adema GJ: In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 64: 4024-4029, 2004.
18. Baronzio G, Gramaglia A and Fiorentini G: Hyperthermia and immunity. A brief overview. In Vivo 20: 689-695, 2006.
19. Zerbini A, Pilli M, Penna A, et al: Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res 66: 1139-1146, 2006.
20. Mukhopadhyaya A, Mendecchi J, Dong X, Figdor CG, Ruers TJ and Adema GJ: Hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity. Cancer Res 67: 7798-7806, 2007.
21. Zhang HG, Mehta K, Cohen P and Guha C: Hyperthermia on immune regulation: a temperature’s story. Cancer Res 67: 1139-1146, 2007.
22. Gouttefangeas C: More than just tumor destruction: immune modulation by thermal ablation of cancer. Clin Dev Immunol 2011: 160250, 2011.
23. Takagi H, et al: 4-S-Cysteaminylandphenol-loaded magnetite cationic liposomes for combination therapy of hyperthermia with chemotherapy against malignant melanoma. Cancer Sci 98: 424-430, 2007.